This video is entirely AI generated and does not replicate any original material. It should not be considered a substitute for authentic sources. For complete context and techniques, viewers are encouraged to refer to the original content.
Based on findings from:
-
SimBioSys Secures FDA Clearance for TumorSight® Risk, Introducing the World's First AI-Powered, MRI-Derived Breast Cancer Recurrence Risk Assessment
-
Chatbot Intervention and Cancer Risk Knowledge in Adolescents and Young Adults With Cancer Predisposition
Junne Kamihara, et al.. JAMA Network Open, 2026.
DOI: 10.1001/jamanetworkopen.2026.35794
-
Large language models to support oncology symptom telephone triage: A retrospective pre-implementation evaluation.
Luxiga Thanabalachandran, et al.. JCO Oncology Practice, 2026.
DOI: 10.1200/OP.2026.22.10_suppl.672
Weekly News Brief: October 19–23, 2026
To catch up on all of the news from this past week, listen to our weekly news brief for the week of October 19–23, 2026.
This week’s brief covers FDA clearance of an MRI-based breast cancer recurrence risk tool, evidence that supervised large language models can match trainees in nurse-led telephone triage, and a trial showing a chatbot raises cancer risk awareness in young patients without added distress.
To learn more about TumorSight Risk, read "FDA Clears MRI-Based Prognostic Tool for Recurrence Risk in HR-Positive Breast Cancer," or see the press release.
For more information on AYA-RISE, read "Chatbot Improves Cancer Risk Awareness in Young Patients," or see the source report in JAMA Network Open.
To learn more about real-world oncology symptom telephone triage, read "Human-Supervised LLMs Show Promise for Streamlining Nurse-Led Oncology Telephone Triage," or see the abstract.
Disclaimer: This newscast was generated with the assistance of AI tools and avatars. All content is reviewed and approved by the editorial staff of ASCO AI in Oncology. Contact us with any questions.
The ideas and opinions expressed in ASCO AI in Oncology do not necessarily reflect those of Conexiant or ASCO. The mention of any company, product, service, or therapy should not be construed as an endorsement of any kind. Conexiant and ASCO assume no responsibility for any injury or damage to persons or property arising out of or related to any use of material contained in this publication or to any errors or omissions.